This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, p…

Hereditary AngioedemaHAEHereditary Angioedema - Type 1+1 more

~Estimated

~$10 – $8,750

ADARx Pharmaceuticals, Inc.NCT06960213

Phase 3

A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the saf…

Hereditary Angioedema (HAE)Hereditary Angioedema - Type 1Hereditary Angioedema - Type 2+1 more

~Estimated

~$10 – $8,750

ADARx Pharmaceuticals, Inc.NCT07428499